These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20007955)

  • 1. Predicting the response to infliximab from trough serum levels.
    Rutgeerts P; Vermeire S; Van Assche G
    Gut; 2010 Jan; 59(1):7-8. PubMed ID: 20007955
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'Predicting the response to infliximab from trough serum levels'.
    Bendtzen K; Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J
    Gut; 2010 Sep; 59(9):1298-9; author reply 1299-300. PubMed ID: 20801776
    [No Abstract]   [Full Text] [Related]  

  • 3. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab in ulcerative colitis.
    Böcker U
    Scand J Gastroenterol; 2006 Sep; 41(9):997-1000. PubMed ID: 16938710
    [No Abstract]   [Full Text] [Related]  

  • 7. Infliximab for refractory ulcerative proctitis.
    Bouguen G; Roblin X; Bourreille A; Feier L; Filippi J; Nancey S; Bretagne JF; Flourié B; Hébuterne X; Bigard MA; Siproudhis L; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2010 Jun; 31(11):1178-85. PubMed ID: 20222911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula.
    Hassan C; Zullo A; Ierardi E; Burattini O; De Francesco V; Morini S
    Gut; 2006 Apr; 55(4):589-90. PubMed ID: 16531548
    [No Abstract]   [Full Text] [Related]  

  • 9. Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms.
    Lupascu A; Armuzzi A; De Pascalis B; Carloni E; Lauritano EC; Gasbarrini A; Pola P; Gasbarrini A
    Dig Liver Dis; 2004 Jun; 36(6):423-5. PubMed ID: 15248384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab or cyclosporine for severe ulcerative colitis.
    Hanauer SB
    Gastroenterology; 2005 Oct; 129(4):1358-9; author reply 1359. PubMed ID: 16230092
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
    Jakobovits SL; Jewell DP; Travis SP
    Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in refractory severe ulcerative colitis: a case report.
    Bossa F; Caserta L; Selvaggi F; Riegler G
    Minerva Gastroenterol Dietol; 2005 Sep; 51(3):261-2. PubMed ID: 16280968
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab therapy for ulcerative colitis: many unanswered questions.
    Present DH
    Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
    [No Abstract]   [Full Text] [Related]  

  • 15. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adapting the dose to the residual concentration of infliximab in cryptogenic inflammatory diseases of the intestines].
    Chanson P; Pariente A
    Rev Prat; 2015 Apr; 65(4):473. PubMed ID: 26058185
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab for refractory ulcerative colitis.
    Chey WY; Hussain A; Ryan C; Potter GD; Shah A
    Am J Gastroenterol; 2001 Aug; 96(8):2373-81. PubMed ID: 11513177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates.
    Halpin SJ; Hamlin PJ; Ford AC
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1294-5. PubMed ID: 20955450
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab or cyclosporine for severe ulcerative colitis.
    Järnerot G
    Gastroenterology; 2006 Jan; 130(1):286; author reply 287. PubMed ID: 16401502
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab rescue therapy in steroid-refractory ulcerative colitis: is more really more?
    Molnár T; Farkas K; Szepes Z; Nagy F; Wittmann T
    Aliment Pharmacol Ther; 2011 Feb; 33(3):412-3. PubMed ID: 21198699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.